A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
Condition(s):B-cell Non-Hodgkin’s LymphomaLast Updated:October 25, 2021Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):B-cell Non-Hodgkin’s LymphomaLast Updated:October 25, 2021Not yet recruiting
Condition(s):B-Cell Non-Hodgkin’s LymphomaLast Updated:December 15, 2022Recruiting
Condition(s):Relapsed/Refractory B-cell Non-Hodgkin LymphomaLast Updated:March 15, 2024Recruiting
Condition(s):B-cell Non-Hodgkins Lymphoma (B-NHL)Last Updated:December 21, 2023Recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:November 8, 2023Active, not recruiting
Condition(s):B-cell Non Hodgkin LymphomaLast Updated:February 6, 2023Recruiting
Condition(s):Relapsed or Refractory B Cell Non-Hodgkin LymphomaLast Updated:March 28, 2024Recruiting
Condition(s):CD20-positive B-cell Non-Hodgkin’s LymphomaLast Updated:April 10, 2023Recruiting
Condition(s):Relapsed/Refractory B-cell Non-Hodgkin’s LymphomaLast Updated:February 9, 2023Unknown status
Condition(s):Relapsed or Refractory B-cell Non-Hodgkin’s LymphomaLast Updated:December 16, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.